Bayer Suspends Trasylol Marketing At FDA’s Behest

Law360, New York (November 5, 2007, 12:00 AM EST) -- Amid mounting concerns over the safety of Bayer Pharmaceuticals Corp.’s Trasylol, the pharmaceutical giant on Monday agreed to temporarily suspend worldwide marketing of the blood-clotting drug pending a review of preliminary results from a Canadian study that pointed to an increased risk of death.

The U.S. Food and Drug Administration said Monday that it had requested the suspension in the interest of patient safety based on the “serious nature” of the outcomes suggested by the preliminary data.

The agency said it had not yet received the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.